your own website. You may ... that modulate the enzymatic activity of CYP will be de- scribed that ... Thirdly, an analysis based on a review of the literature will.
Cytochrome P450 interactions and clinical implication in rheumatology
Audrey Cayot, Davy Laroche, Anne Disson-Dautriche, Anaïs Arbault, JeanFrancis Maillefert & Paul Ornetti Clinical Rheumatology Journal of the International League of Associations for Rheumatology ISSN 0770-3198 Clin Rheumatol DOI 10.1007/s10067-014-2710-3
1 23
Your article is protected by copyright and all rights are held exclusively by Clinical Rheumatology. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com”.
1 23
Author's personal copy Clin Rheumatol DOI 10.1007/s10067-014-2710-3
REVIEW ARTICLE
Cytochrome P450 interactions and clinical implication in rheumatology Audrey Cayot & Davy Laroche & Anne Disson-Dautriche & Anaïs Arbault & Jean-Francis Maillefert & Paul Ornetti
Received: 27 May 2014 / Accepted: 30 May 2014 # Clinical Rheumatology 2014
Abstract There are many potential drug interactions that involve the complex cytochromes P450 (CYP) enzyme system when treatments for chronic inflammatory rheumatic diseases are used. This iatrogenic risk is increased in patients taking multiple drugs such as those with rheumatoid arthritis or gout, whatever the type of CYP interaction (substrate, inducer, or inhibitor of one of the CYP isoenzymes). Some of these CYP interactions may have clinical consequences, sometimes serious (overdose or therapeutic failure) and are often unrecognized by clinicians. The aim of this article is first of all to act as a reminder of the metabolic role of membrane-bound CYP enzymes in the liver in the oxidation of drugs and the potential types of interaction (drug substrate, inducer, or inhibitor or indirectly by the modulation of CYP activity through its powerful antiinflammatory activity). Secondly, the different factors that modulate the enzymatic activity of CYP will be described that may contribute to variations in drug metabolism and therefore modify the benefit-risk ratio of the drug. Thirdly, an analysis based on a review of the literature will present the different known interactions via CYP for drugs A. Cayot : A. Arbault : J.
